1. Home
  2. LCTX vs MRCC Comparison

LCTX vs MRCC Comparison

Compare LCTX & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • MRCC
  • Stock Information
  • Founded
  • LCTX 1990
  • MRCC 2011
  • Country
  • LCTX United States
  • MRCC United States
  • Employees
  • LCTX N/A
  • MRCC N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • MRCC Investment Managers
  • Sector
  • LCTX Health Care
  • MRCC Finance
  • Exchange
  • LCTX Nasdaq
  • MRCC Nasdaq
  • Market Cap
  • LCTX 166.3M
  • MRCC 174.8M
  • IPO Year
  • LCTX N/A
  • MRCC 2012
  • Fundamental
  • Price
  • LCTX $0.91
  • MRCC $8.26
  • Analyst Decision
  • LCTX Strong Buy
  • MRCC Strong Buy
  • Analyst Count
  • LCTX 3
  • MRCC 1
  • Target Price
  • LCTX $5.67
  • MRCC $9.00
  • AVG Volume (30 Days)
  • LCTX 442.0K
  • MRCC 63.6K
  • Earning Date
  • LCTX 11-14-2024
  • MRCC 11-12-2024
  • Dividend Yield
  • LCTX N/A
  • MRCC 12.15%
  • EPS Growth
  • LCTX N/A
  • MRCC 298.01
  • EPS
  • LCTX N/A
  • MRCC 0.60
  • Revenue
  • LCTX $6,186,000.00
  • MRCC $62,007,000.00
  • Revenue This Year
  • LCTX N/A
  • MRCC N/A
  • Revenue Next Year
  • LCTX $123.52
  • MRCC N/A
  • P/E Ratio
  • LCTX N/A
  • MRCC $13.75
  • Revenue Growth
  • LCTX N/A
  • MRCC N/A
  • 52 Week Low
  • LCTX $0.77
  • MRCC $6.77
  • 52 Week High
  • LCTX $1.61
  • MRCC $8.41
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 55.63
  • MRCC 57.95
  • Support Level
  • LCTX $0.88
  • MRCC $7.97
  • Resistance Level
  • LCTX $0.97
  • MRCC $8.18
  • Average True Range (ATR)
  • LCTX 0.04
  • MRCC 0.15
  • MACD
  • LCTX 0.01
  • MRCC 0.03
  • Stochastic Oscillator
  • LCTX 71.56
  • MRCC 86.60

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

Share on Social Networks: